期刊文献+

^131I首次清除分化型甲状腺癌残留组织的影响因素探讨 被引量:3

The effect factors of first iodine- 131 ablation of thyroid remnants in patients with differentiated thyroid cancer
原文传递
导出
摘要 目的观察^131I首次“清甲”的疗效及分析其影响因素。方法确诊分化型甲状腺癌(DTC)患者经手术治疗后行^131I治疗,然后按手术方式、术后治疗时间^131I的剂量进行分类,观察首次“清甲”的疗效。结果“清甲”成功率:甲状腺全切88.5%,次全切除44.4%;“清甲”时间术后1~2个月92.7%,1年以上50.0%;^131I剂量2.96GBq为47.6%,4.44GBq为82.8%。结论DTC治疗应以甲状腺全切及颈淋巴结清扫为首选治疗方式,术后1~2个月为^131I“清甲”最佳时机,首次“清甲”^131I剂量以4.44GBq(120mci)为宜。 Objective To observe the effect of the first iodine - 131 ablation of thyroid remnants in patients with differentiated thyroid cancer (DTC) and discuss factors that may be influential in the treatment. Methods All DTC patients confirmed by pathology received iodine - 131 therapy after necessary preparation. According different operation procedures, time interval between operation and iodine - 131 treatment and dose of iodine - 131, the patients were divided into different groups. Therapy effects were observed in different groups. Results Ablation successful rate was 88.5% in total thyroidectomy group, compared with 44.4% in subtotal tbyroidectomy group. 92.7% ablation rate was seen in the group of 1 -2 months time interval between operation and iodine - 131 treatment, while in the group of over 1 year time interval, only 50% ablationrate was achieved. Ablation successful rate was 47.6% in the group of low dose of iodine - 131 ( 2.96GBq), compared with 82.8% in the high dose group (4.44GBq). Conclusions Total thyroidectomy and cervical lymph nodes dissection should be recommended for the patients with DTC. The better interval time between operation and iodine - 131 ablation thyroid remnants is 1 -2 months. The high dose of iodine - 131 shows better result than low dose of iodine - 131 treatment.
作者 敬兴果 程刚
出处 《中华内分泌外科杂志》 CAS 2009年第3期167-169,共3页 Chinese Journal of Endocrine Surgery
关键词 分化型甲状腺癌术后 ^131I碘清除 Differentiated thyroid cancer (DTC) Iodine- 131 ablation
  • 相关文献

同被引文献26

  • 1罗全勇,朱瑞森.^(131)I与甲状腺顿抑[J].中华核医学杂志,2004,24(4):252-253. 被引量:2
  • 2Hodgson NC, Button J, Solorzano CC. Thyroid cancer: is the incidence still increasing? [J]. Ann Surg Oncol, 2004, 11(12): 1093-1097.
  • 3Eustaia-Rutten CF, Corssmit EP, Biermasz NR, et al. Survival and death causes in differentiated thyroid carcinoma [J]. J Clin Endocrinol Metab,2006,91 ( 1 ):313-319.
  • 4Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma[J]. Lancet Oncol, 2007, 8(2):148-156.
  • 5Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer [J]. Thyroid, 2009,19(11):1167-1214.
  • 6Luster M, Clarke SE, Dietlein M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer[J]. Eur J Nucl Med Mol Imaging,2008,35(10): 1941-1959.
  • 7Biermann M, Pixberg MK, Dorr U, et al.Guidelines on radioiodine therapy for differentiated thyroid carcinoma: impact on clinical practice[J]. Nucl Med, 2005, 44(6): 229-234.
  • 8刘春萍,李治,黄韬.分化型甲状腺癌430例手术方式与并发症分析[J].中国实用外科杂志,2007,27(11):895-896. 被引量:13
  • 9李少林.核医学[M]北京:人民卫生出版社,2004241.
  • 10I.eeman - Neill R J, Brenner AV, Little MP, et al. RET/PTC and PAX8/PPAR γ chromosomal rearrangements in post - Chernobyl thyroid cancer and their association with iodine - 131 radiation dose and other characteristics [ J]. Cancer, 2013, 119 (10) : 1792 - 1799.

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部